Roquefort Therapeutics (LON:ROQ) Trading Down 1.9% – Should You Sell?

Shares of Roquefort Therapeutics plc (LON:ROQ) traded down 1.9% during mid-day trading on Wednesday . The stock traded as low as GBX 1.74 ($0.02) and last traded at GBX 1.82 ($0.02). 694,002 shares were traded during trading, a decline of 74% from the average session volume of 2,688,093 shares. The stock had previously closed at GBX 1.85 ($0.02).

Roquefort Therapeutics Stock Down 10.0 %

The company has a debt-to-equity ratio of 12.37, a quick ratio of 3.07 and a current ratio of 0.79. The company has a market cap of £2.12 million, a P/E ratio of -1.37 and a beta of 0.05. The stock has a 50 day moving average price of GBX 1.78 and a 200 day moving average price of GBX 3.15.

Insiders Place Their Bets

In related news, insider Stephen Paul West acquired 400,000 shares of the business’s stock in a transaction dated Tuesday, February 4th. The stock was bought at an average price of GBX 3 ($0.04) per share, for a total transaction of £12,000 ($16,094.42). 60.40% of the stock is owned by company insiders.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.